




or



The present disclosure provides use of an effective amount of an antibody drug conjugate (ADC) composition comprising an IgG antibody that binds to c-Met, a conjugation linker moiety that binds to both Cys residues in the hinge region of an IgG antibody and a toxin moiety, in the manufacture of a medicament for treating breast cancer.

The present disclosure provides a method for treating breast cancer, comprising administering an effective amount of an antibody drug conjugate (ADC) composition comprising an IgG antibody that binds to c-Met, a conjugation linker moiety that binds to both Cys residues in the hinge region of an IgG antibody and a toxin moiety. Preferably, the toxin moiety is a tubulin inhibitor or a doxorubicin analog. Preferably, the antibody is an IgG antibody from the H8 (heavy/light SEQ ID NOs 19/20) family or is a B12 (heavy/light SEQ ID NOs 7/8), wherein the H8 antibody family is selected from the group consisting of H8-A2, H8-9, H8-9EE8L3, H8-C1, H8-D4, H8-D5, H8-D6, H8-D10, H8-E5, H8-G7, H8-H6, H8-2A2, H8-2B1, H8-2B2, H8-2B4, H8-2B7, H8-A7P, H8-9EH11L, H8-9EH11L, and H8-6AG2H3. Preferably, the conjugated toxin is



or

0276 Structure for conjugation and drug


We claim:

1. An antibody drug conjugate (ADC) composition comprising an IgG antibody that binds to c-Met, a conjugation linker moiety that binds to both Cys residues in the hinge region of an IgG antibody and a toxin moiety.


2. The ADC composition of claim 1, wherein the toxin moiety is a tubulin inhibitor or a doxorubicin analog.

3. The ADC composition of claim 1, wherein the antibody is an IgG antibody from the H8 (heavy/light SEQ ID NOs 19/20) family or is a B12 (heavy/light SEQ ID NOs 7/8), wherein the H8 antibody family is selected from the group consisting of H8-A2, H8-9, H8-9EE8L3, H8-C1, H8-D4, H8-D5, H8-D6, H8-D10, H8-E5, H8-G7, H8-H6, H8-2A2, H8-2B1, H8-2B2, H8-2B4, H8-2B7, H8-A7P, H8-9EH11L, H8-9EH11L, and H8-6AG2H3.

4. The ADC composition of claim 1, wherein the conjugated toxin is



or




5. Use of an effective amount of an antibody drug conjugate (ADC) composition comprising an IgG antibody that binds to c-Met, a conjugation linker moiety that binds to both Cys residues in the hinge region of an IgG antibody and a toxin moiety, in the manufacture of a medicament for treating breast cancer.

6. The use for treating breast cancer of claim 5, wherein the toxin moiety is a tubulin inhibitor or a doxorubicin analog.

7. The use for treating breast cancer of claim 5, wherein the antibody is an IgG antibody from the H8 (heavy/light SEQ ID NOs 19/20) family or is a B12 (heavy/light SEQ ID NOs 7/8), wherein the H8 antibody family is selected from the group consisting of H8-A2, H8-9, H8-9EE8L3, H8-C1, H8-D4, H8-D5, H8-D6, H8-D10, H8-E5, H8-G7, H8-H6,

H8-2A2, H8-2B1, H8-2B2, H8-2B4, H8-2B7, H8-A7P, H8-9EH11L, H8-9EH11L, and H8-6AG2H3.

8. The use for treating breast cancer of claim 5, wherein the conjugated toxin is



or

